How Trump's tariffs have created 'upside potential' for CSL shares

A leading expert says CSL shares are now looking 'cheap'.

| More on:
Shot of a scientist using a computer while conducting research in a laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

CSL Ltd (ASX: CSL) shares have gone backwards over the past year.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock closed up 0.99% on Monday trading for $244.29.

Despite that welcome boost, shares remain down 10.61% in 12 months, underperforming the 5.56% gains posted by the ASX 200 over this same time.

Although it's worth noting that those losses will have been modestly mitigated by CSL's dividends. The stock trades on an unfranked trailing dividend yield of 1.7%.

While CSL shares have been under selling pressure since last August, United States President Donald Trump's indication that imported medicines may get hit with tariffs hasn't done shareholders any favours.

But, according to Catapult Wealth's Dylan Evans, the market's reaction to those as-yet undeclared tariffs could make now an opportune time to buy stock in CSL (courtesy of The Bull).

Why CSL shares are a buy

"The share price of this biotechnology giant has been trending down since mid-2024," said Evans, who has a buy recommendation on CSL shares.

Commenting on Trump's tariff warnings, he said, "Threats from the Trump Administration to extend tariffs to imported pharmaceuticals would possibly have a negative impact on CSL, given it generates around half its revenue in the US."

But that isn't dissuading him from buying the biotech stock.

"Despite these risks, we believe CSL represents good value," Evans said. "It remains a high quality company, delivering double digit earnings growth. It looks cheap compared to global peers."

And with the market having already discounted CSL amid expectations of those tariffs, Evans noted, "The impact of US tariffs is factored into the share price, so, in our view, there's upside potential if they are withdrawn, or lower than anticipated."

Also bullish on the ASX 200 biotech stock

Tyndall Asset Management's Tim Johnston also has a bullish outlook for CSL shares (courtesy of The Australian Financial Review).

Atop headwinds from potential US tariffs on pharmaceuticals, CSL has also come under pressure following the confirmation of Robert F Kennedy junior, a vaccine sceptic, as US health and human services secretary.

At the company's half-year results (H1 FY 2025), CSL already reported a 9% decline in revenue at Seqirus, its vaccine division. That was driven by low immunisation rates, especially in the US.

But Johnston doesn't believe these headwinds will persist for CSL shares.

"Common sense will prevail, science will win out," he said of the US vaccination rates.

"And CSL at 21 times earnings for a stock that's probably going to deliver low double-digit earnings growth for the foreseeable future is as cheap as I have seen it," Johnston said.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »